Details of the Drug Combinations

General Information of This Drug (ID: DMA6RBF)

• Drug Name: GSK1325756 (DMA6RBF)
• Synonyms: Danirixin; 954126-98-8; GSK1325756; UNII-R318PGH5VP; GSK-1325756B; R318PGH5VP; GSK1325756B; Danirixin [USAN:INN]; GSK-1325756; GSK 1325756; Danirixin (USAN/INN); Danirixin(GSK1325756); GTPL8500; SCHEMBL1198688; CHEMBL3039531; MolPort-044-561-791; EX-A1178; ZINC95627831; AKOS030527036; DB11922; CS-5465; 1-(4-Chloro-2-hydroxy-3-(((3S)-piperidine-3-sulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea; HY-19768; D10387; (S)-1-(4-chloro-2-hydroxy-3-(piperidin-3-ylsulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea

Indication

Chronic obstructive pulmonary disease; ICD 11: CA22; Status: Phase 2 [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
GSK1325756 + Panobinostat	DCLGH72	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Omeprazole + GSK1325756	DCF4525	Omeprazole	Pulmonary Disease, Chronic Obstructive	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8500).
• [2] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [3] ClinicalTrials.gov (NCT03457727) GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects